Targeting microRNA-33 to reduce intracranial atherosclerosis and other neurovascular hallmarks of vascular cognitive impairment and dementia

靶向 microRNA-33 减少颅内动脉粥样硬化以及血管性认知障碍和痴呆的其他神经血管标志

基本信息

  • 批准号:
    9765860
  • 负责人:
  • 金额:
    $ 42.08万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-04-01 至 2022-03-31
  • 项目状态:
    已结题

项目摘要

Project Summary Intracranial atherosclerosis (ICAS) is a public health concern for both its role in stroke and as a contributing factor to vascular cognitive impairment and dementia (VCID). It is becoming widely accepted that poor vascular health facilitates poor brain health and that changes are needed to delay or prevent onset of VCID. Atherosclerotic vascular disease (AVD) is a chronic, maladaptive inflammatory disease that can affect extra- and intracranial arteries. The combination of lipoprotein retention, endothelial cell inflammation, monocyte/macrophage infiltration, intracellular cholesterol accumulation, impaired apoptotic cell clearance, and extracellular matrix degradation leads to formation of advanced, unstable atherosclerotic plaques that can limit or occlude blood flow to tissues causing acute or chronic tissue damage. ICAS often plays a causative role in ischemic stroke and subsequent cognitive decline. ICAS has also been linked to both clinical signs of cognitive decline and Alzheimer's disease pathology. Intracranial compared to extracranial atherosclerosis has a delayed onset of ~20 years but increases in prevalence and severity in individuals 60 years or older. With the steady rise in the percentage of US citizens above the age of 60, ICAS will play an ever-growing role in the morbidity and mortality caused by VCID. Reducing low-density lipoprotein (LDL) concentration with statins is a primary therapeutic approach to stabilize AVD and attenuate ischemic stroke risk. However, statins only reduce stroke risk by ~20% and do not appear to reduce VCID suggesting that treating hypercholesterolemia alone is not an ideal approach for reducing VCID. The obvious need for additional therapies that regress or stabilize ICAS has been hampered by the paucity of suitable animal models. During an R01-funded study to determine the impact of microRNA-33 (miR-33) antagonism on cardiovascular AVD, we fortuitously discovered that our NHP model had ICAS and other neurovascular hallmarks of VCID. We believe analysis of intracranial arteries and brains from our NHPs could have a high impact on the field of VCID research because of the potential discovery of a new therapy and animal model for VCID.
项目摘要 颅内动脉粥样硬化(ICAS)是一个公共卫生问题,因为它在中风中的作用和作为一个促成因素 血管性认知损害和痴呆(VCID)的因素。人们越来越普遍地认为,血管质量差 健康促进大脑健康不良,需要改变以延迟或预防VCID的发病。 动脉粥样硬化性血管疾病(AVD)是一种慢性、不适应的炎症性疾病,可影响外部和外部 颅内动脉。脂蛋白滞留,内皮细胞炎症, 单核/巨噬细胞浸润,细胞内胆固醇积聚,细胞凋亡清除受损,以及 细胞外基质降解导致晚期不稳定动脉粥样硬化斑块的形成 或阻断流向组织的血液,造成急性或慢性组织损伤。ICAS通常在以下方面发挥因果作用 缺血性中风和随后的认知能力下降。ICAS也被认为与认知能力的临床症状 衰弱与阿尔茨海默病的病理。与颅外动脉粥样硬化相比,颅内动脉粥样硬化有延迟 发病年龄约为20岁,但在60岁或以上的人中患病率和严重性有所增加。有了稳定的 随着美国60岁以上公民比例的上升,ICAS在发病率中将发挥越来越大的作用 以及由VCID引起的死亡。使用他汀类药物降低低密度脂蛋白(LDL)浓度是主要的 稳定AVD和降低缺血性中风风险的治疗方法。然而,他汀类药物只能减少中风 风险降低约20%,而且似乎不能减少VCID,这表明单独治疗高胆固醇血症并不是 减少VCID的理想方法。显然需要更多的治疗方法来消退或稳定ICAS 由于缺乏合适的动物模型而受到阻碍。在一项由R01资助的研究期间,以确定 关于microRNA-33(miR-33)对心血管AVD的拮抗作用,我们偶然发现我们的NHP模型 有ICAS和其他VCID的神经血管特征。我们相信对颅内动脉和大脑的分析 可能对VCID研究领域产生很大影响,因为可能会发现一种 VCID的新疗法和动物模型。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ryan Eugene Temel其他文献

Ryan Eugene Temel的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ryan Eugene Temel', 18)}}的其他基金

Effects of Anti-miR-33 on Atherosclerosis Regression and RCT in Nonhuman Primates
抗 miR-33 对非人灵长类动物动脉粥样硬化消退和 RCT 的影响
  • 批准号:
    8438869
  • 财政年份:
    2013
  • 资助金额:
    $ 42.08万
  • 项目类别:
Effects of Anti-miR-33 on Atherosclerosis Regression and RCT in Nonhuman Primates
抗 miR-33 对非人灵长类动物动脉粥样硬化消退和 RCT 的影响
  • 批准号:
    8968259
  • 财政年份:
    2013
  • 资助金额:
    $ 42.08万
  • 项目类别:
Effects of Anti-miR-33 on Atherosclerosis Regression and RCT in Nonhuman Primates
抗 miR-33 对非人灵长类动物动脉粥样硬化消退和 RCT 的影响
  • 批准号:
    8774254
  • 财政年份:
    2013
  • 资助金额:
    $ 42.08万
  • 项目类别:
Effects of Anti-miR-33 on Atherosclerosis Regression and RCT in Nonhuman Primates
抗 miR-33 对非人灵长类动物动脉粥样硬化消退和 RCT 的影响
  • 批准号:
    9352511
  • 财政年份:
    2013
  • 资助金额:
    $ 42.08万
  • 项目类别:
Effects of Anti-miR-33 on Atherosclerosis Regression and RCT in Nonhuman Primates
抗 miR-33 对非人灵长类动物动脉粥样硬化消退和 RCT 的影响
  • 批准号:
    9181440
  • 财政年份:
    2013
  • 资助金额:
    $ 42.08万
  • 项目类别:
Effects of Anti-miR-33 on Atherosclerosis Regression and RCT in Nonhuman Primates
抗 miR-33 对非人灵长类动物动脉粥样硬化消退和 RCT 的影响
  • 批准号:
    8605546
  • 财政年份:
    2013
  • 资助金额:
    $ 42.08万
  • 项目类别:
Mechanisms For PPARdelta Agonist-Induced Elevation of HDL in Non-Human Primates
PPARδ 激动剂诱导非人灵长类动物 HDL 升高的机制
  • 批准号:
    8018108
  • 财政年份:
    2009
  • 资助金额:
    $ 42.08万
  • 项目类别:
Mechanisms For PPARdelta Agonist-Induced Elevation of HDL in Non-Human Primates
PPARδ 激动剂诱导非人灵长类动物 HDL 升高的机制
  • 批准号:
    7760739
  • 财政年份:
    2009
  • 资助金额:
    $ 42.08万
  • 项目类别:
Mechanisms For PPARdelta Agonist-Induced Elevation of HDL in Non-Human Primates
PPARδ 激动剂诱导非人灵长类动物 HDL 升高的机制
  • 批准号:
    7769906
  • 财政年份:
    2009
  • 资助金额:
    $ 42.08万
  • 项目类别:
Mechanisms For PPARdelta Agonist-Induced Elevation of HDL in Non-Human Primates
PPARδ 激动剂诱导非人灵长类动物 HDL 升高的机制
  • 批准号:
    7250977
  • 财政年份:
    2006
  • 资助金额:
    $ 42.08万
  • 项目类别:

相似海外基金

Hormone therapy, age of menopause, previous parity, and APOE genotype affect cognition in aging humans.
激素治疗、绝经年龄、既往产次和 APOE 基因型会影响老年人的认知。
  • 批准号:
    495182
  • 财政年份:
    2023
  • 资助金额:
    $ 42.08万
  • 项目类别:
Investigating how alternative splicing processes affect cartilage biology from development to old age
研究选择性剪接过程如何影响从发育到老年的软骨生物学
  • 批准号:
    2601817
  • 财政年份:
    2021
  • 资助金额:
    $ 42.08万
  • 项目类别:
    Studentship
RAPID: Coronavirus Risk Communication: How Age and Communication Format Affect Risk Perception and Behaviors
RAPID:冠状病毒风险沟通:年龄和沟通方式如何影响风险认知和行为
  • 批准号:
    2029039
  • 财政年份:
    2020
  • 资助金额:
    $ 42.08万
  • 项目类别:
    Standard Grant
Neighborhood and Parent Variables Affect Low-Income Preschool Age Child Physical Activity
社区和家长变量影响低收入学龄前儿童的身体活动
  • 批准号:
    9888417
  • 财政年份:
    2019
  • 资助金额:
    $ 42.08万
  • 项目类别:
The affect of Age related hearing loss for cognitive function
年龄相关性听力损失对认知功能的影响
  • 批准号:
    17K11318
  • 财政年份:
    2017
  • 资助金额:
    $ 42.08万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
  • 批准号:
    9320090
  • 财政年份:
    2017
  • 资助金额:
    $ 42.08万
  • 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
  • 批准号:
    10166936
  • 财政年份:
    2017
  • 资助金额:
    $ 42.08万
  • 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
  • 批准号:
    9761593
  • 财政年份:
    2017
  • 资助金额:
    $ 42.08万
  • 项目类别:
How age dependent molecular changes in T follicular helper cells affect their function
滤泡辅助 T 细胞的年龄依赖性分子变化如何影响其功能
  • 批准号:
    BB/M50306X/1
  • 财政年份:
    2014
  • 资助金额:
    $ 42.08万
  • 项目类别:
    Training Grant
Inflamm-aging: What do we know about the effect of inflammation on HIV treatment and disease as we age, and how does this affect our search for a Cure?
炎症衰老:随着年龄的增长,我们对炎症对艾滋病毒治疗和疾病的影响了解多少?这对我们寻找治愈方法有何影响?
  • 批准号:
    288272
  • 财政年份:
    2013
  • 资助金额:
    $ 42.08万
  • 项目类别:
    Miscellaneous Programs
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了